Rule 49 of the Patents Rules, 2003
Omitted provision
Rule 49 was the opening rule of the old Exclusive Marketing Rights chapter of the Patents Rules and no longer has any effect.
Official legal text
This provision has been omitted, but its number remains. Statutes here are amended by omission rather than renumbering, which keeps every other number stable. Anyone reading a file, an order or a commentary from the period when it applied will meet this number and need to know what it covered.
Nothing here replaces the statute. The official wording of the provision, together with any Gazette notification that applies to it, governs. This page only explains that material in ordinary language.
What this rule requires, step by step
Rule 49 belonged to Chapter V of the Patents Rules, 2003, a chapter headed Exclusive Marketing Rights. An Exclusive Marketing Right, usually shortened to EMR, was a temporary commercial right that allowed one company to sell a particular medicine or agricultural chemical in India for a limited time, even though no patent had yet been granted for it. Chapter V carried the paperwork side of that scheme, and Rule 49 sat at the front of it. The scheme itself came from Chapter IVA of the Patents Act, 1970, which was inserted by the Patents (Amendment) Act, 1999 to meet India's obligations after it joined the World Trade Organization in 1995.
The whole arrangement was designed to end, and it did. From 1 January 2005 India began granting product patents for medicines, food and agricultural chemicals, so a stop-gap marketing right was no longer needed. The Patents (Amendment) Act, 2005 deleted Chapter IVA from the Act, and the matching rules in Chapter V, including Rule 49, were dropped from the Rules. Nothing can be filed under this rule today and no live right depends on it. A reader studying how India moved from process patents to product patents will still meet the number in older commentaries, but for any current filing the relevant procedure is found in the ordinary application and examination rules.
Why this rule matters
Researchers, students and lawyers reading pre-2005 material on Indian pharmaceutical patents; nobody filing today.
Only when studying the history of the Act or reading an old file that mentions Chapter V.
No current right or duty at all; it is a repealed procedural rule kept in the numbering for continuity.
Nothing is lost by ignoring it, but citing it as live law in a submission looks careless and can mislead a client.
How it works in practice
A student traces an old pharmaceutical file
Ananya Rao, a law student at a Hyderabad university, is writing a dissertation on how India met its World Trade Organization commitments. She finds a 2004 note in a public archive about a medicine sold in India by a single company although no Indian patent existed for it. The note cites Chapter V of the Patents Rules and mentions Rule 49. Ananya assumes the rule is still in force and begins drafting a section on how EMR applications are made today. Her supervisor stops her. He explains that the Patents (Amendment) Act, 2005 removed the Exclusive Marketing Rights chapter from the Act, and the supporting rules went with it. Ananya rewrites the chapter as legal history, explaining that from 2005 the same medicine would be dealt with through an ordinary patent application, publication, examination and grant. Her dissertation is stronger for saying clearly that the rule is dead, and she adds a footnote warning other students not to cite Chapter V as current procedure.
Simplified illustration only. Actual legal outcomes depend on the facts.
Key points to remember
- Rule 49 formed part of Chapter V of the Patents Rules, 2003, dealing with Exclusive Marketing Rights.
- Exclusive Marketing Rights were a temporary bridge before India allowed product patents for medicines and agrochemicals.
- The Patents (Amendment) Act, 2005 removed the parent provisions and this rule was omitted with them.
- No application, form or fee can be filed under Rule 49 today.
Connected provisions
Because this page covers a rule rather than a section, the related Act provisions are shown in their own list. The section tells you what the law requires. The rule, explained above, tells you how the Patent Office expects that requirement to be met.
Forms, deadlines and fees
Fees are prescribed in the First Schedule to the Patents Rules. Because the Schedule is revised from time to time, and charges different amounts to different categories of applicant and for physical as against electronic filing, this page describes the fee without stating a figure. How Indian patent fees work.
Related judgments
You will not find case summaries under this heading today. Each one must pass a legal review before it appears, and that work has not been completed for this provision. If you are researching decided cases, use a law report or a court database in the meantime. How case notes are prepared.
Questions people ask about Rule 49
Can I still apply for an exclusive marketing right in India?
No. Exclusive Marketing Rights were abolished when the Patents (Amendment) Act, 2005 deleted Chapter IVA of the Patents Act, 1970. The rules that supported that chapter, including Rule 49, were omitted at the same time. Since January 2005 India grants product patents for medicines, food and agricultural chemicals, so an applicant simply files an ordinary patent application, has it published and examined, and receives a patent if it qualifies. There is no separate marketing right to apply for and no form for it.
Why is an omitted rule still shown in the Patents Rules?
Rule numbers are not reused. When a rule is removed, the drafters leave the number in place and mark it omitted, so that the numbering of every later rule stays the same. This protects older judgments, textbooks and office files that cite rules by number. It also tells a reader that something once stood there, which is useful when reading historical material. So seeing Rule 49 marked omitted is normal and does not mean the published Rules are incomplete.
Need help with a current Indian patent filing?
MYCrave Consultancy guides inventors and companies through the procedure that actually applies today, from filing to grant.
You will be speaking with MYCrave Consultancy & Services, the firm that operates this platform. General questions are answered free; matter‑specific work is quoted before anything is done.